Clinical trials: Kidney Donors
Renal Failure Chronic, Hepatitis C
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT03093740
- Testing
- Zepatier, Zepatier plus Sofosbuvir
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Delayed Graft Function
TxAccess and Dd-cfDNA for Improved Care of Patients With Delayed Graft Function
This is a prospective multicenter nonrandomized pragmatic hybrid effectiveness-implementation study to test the effectiveness of TxAccess in improving time to renal recovery and immunologic outcomes in patients with delayed graft…
- Trial name
- NCT07825688
- Testing
- TxAccess, Donor-Derived Cell-Free DNA (dd-cfDNA)
- Volunteers
- 450 people
- Sponsor
- Duke University
Kidney Transplant Rejection
Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients
This is a randomized, open-label, controlled clinical trial designed to compare clinical outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR) versus immediate tacrolimus among highly-sensitized…
- Trial name
- NCT04225988
- Testing
- Extended-release tacrolimus, Immediate-release tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Disorder Related to Renal Transplantation, Chronic Kidney Disease
Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients
Endothelial dysfunction one-year after transplantation mainly depends on transplant-associated factors and only marginally on reduced renal function.
- Conditions
- Disorder Related to Renal Transplantation, Chronic Kidney Disease, Endothelial Dysfunction
- Trial name
- CONFUCIUS (NCT02515643)
- Testing
- Endothelial dysfunction
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Renal Failure
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT02945150
- Testing
- elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Function of Renal Transplant
RituxiMab INDuction in Renal Transplantation
Hypothesis: That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival.
- Trial name
- ReMIND (NCT01095172)
- Testing
- Rituximab, Tacrolimus, Mycophenylate mofetil
- Where
- 6 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Endocrine System Diseases, Thyroid Diseases
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
The aim of this study is to assess the impact of endocrine changes and their correction on survival and organ function in heart and lung transplant recipients.
- Conditions
- Endocrine System Diseases, Thyroid Diseases, Cortisol Deficiency, Diabetes Insipidus
- Trial name
- NCT04351945
- Testing
- Blood test
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Acute Kidney Injury, Liver Diseases
Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation
Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in…
- Trial name
- NCT03522688
- Testing
- Dexmedetomidine, Normal saline
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Asan Medical Center
End-Stage Renal Disease
Pediatric Kidney Transplant Without Calcineurin Inhibitors
The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease.
- Trial name
- NCT00023231
- Testing
- Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant Infection, Kidney Transplant Infection
Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant
This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible…
- Conditions
- Liver Transplant Infection, Kidney Transplant Infection, Liver Transplant, Kidney Transplant
- Trial name
- PREVENT (NCT07651137)
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
End Stage Renal Disease
Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
This is a study of patients who have a high risk of kidney rejection before kidney transplant. The hypothesis is that treatment with a medication called rituximab will make it possible for them to receive a kidney transplant from…
- Trial name
- NCT00167791
- Testing
- rituximab
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation
Live Donors for Kidney Transplants
On a yearly basis there are approximately 12,000 kidney transplants in the United States. Presently there are approximately 40,000 patients awaiting a transplant with only 5,000 available donors.
- Trial name
- NCT00001856
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Damage
To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors
The overall goals of this study are to demonstrate the change in renal tubular function in living donors pre and post nephrectomy at 6 months.
- Trial name
- NCT03676361
- Testing
- Desmopressin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Renal Transplant Donor of Left Kidney
Quadratus Lumborum Block Versus Epidural for Laparoscopic Nephrectomy Kidney Donor
This study aimed to compare Quadratus Lumborum Block to Epidural on Stress Response and Perioperative Cellular Immunological Function of Laparoscopic Nephrectomy Kidney Donor
- Trial name
- NCT03520205
- Testing
- Quadratus Lumborum Block, Continuous Epidural
- Where
- Indonesia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Kidney Transplant, Microcirculation
Effects of Dexmedetomidine on Microcirculation and Residual Kidney Function in Kidney Donors
Kidney transplant can help patients with end-stage kidney disease to get rid of dialysis and have a good quality life. However, during the renal donation operation, the stress response and subsequent inflammatory responses may…
- Trial name
- NCT04346290
- Testing
- Dexmedetomidine
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Kidney Failure
CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%
Limiting brain death-induced organ injury through a systemic anti- inflammatory medical management should allow for improvement in the quality of transplanted organs, and as a result, clinical improvement in post-transplant…
- Trial name
- NCT02435732
- Testing
- Heparin, CINRYZE
- Volunteers
- 72 people
- Sponsor
- University of Wisconsin, Madison
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Disorder Related to Renal Transplantation
Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
The purpose of this study is to determine whether Campath-1H induction and the associated lymphocyte depletion will permit long-term rejection-free renal allograft survival in the absence of ongoing corticosteroid administration.
- Trial name
- NCT00167661
- Testing
- Campath-1H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.